AZD1480 is another JAK1/2 tyrosine kinase inhibitor that has shown promising anti-tumor efficacy in an EGFR-driven model of lung adenocarcinoma by inhibiting STAT3 signaling [232,233] but lacked overall clinical activity in human NSCLC patients (NCT01219543 [214]). This evidence concerns the gene EGFR and non-small cell lung carcinoma.